VEGF and Ki-67 Expression in Colorectal Cancer: The Long-Term Impact on Recurrence and Mortality
Objectives: Colorectal cancer is the most frequent and mortal cancer in Portugal. Both angiogenesis and cellular proliferation are core mechanisms to tumoral progression, with VEGF (Vascular Endothelial Growth Factor) and Ki-67, respectively, being widely known markers of those two processes. The purposes of this study are to comprehend VEGF and Ki-67’s impact on colorectal cancer prognosis which include assessing its expression in primary colorectal cancer of patients who underwent surgery, establishing associations between the expression of VEGF and Ki-67 and discovering hypothetical associations between these biomarkers and clinicopathological aspects, relapse, and mortality of patients.
Methods: A retrospective study was conducted in our hospital by including 512 patients submitted to surgery, from 2005 to 2010, with a post-operatory diagnosis of colorectal adenocarcinoma. The evaluation of expression of VEGF and Ki-67 in the obtained tissue was made through immunohistochemistry technique. The statistical analysis resourced to association tests and survival analysis.
Results: VEGF-A showed association with the variable gender (p-value of 0.016), with its expression being more frequent in men. VEGF-C expression is more common in colon than in rectum (p- value of 0.042). VEGF-C is significantly associated with Ki-67 (p-value of 0.036), with 69.7% of cases where both are positive. All markers are significantly associated with the grade of differentiation, with the VEGF family generally more present in well or moderately differentiated tumours and Ki-67 in the poorly differentiated. While the survival time was generally lower in the presence of any marker or combination, no significant differences were found among the survival analysis.
Conclusion: VEGF-A, VEGF-C and Ki-67 expression did not show impact on the prognosis of this sample of patients. There was no significant association with a poorer overall survival or a reduced disease-free survival.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2. Pareceres SPED. Rastreio de cancro colorretal. Available at:https://www.sped.pt/images/Pareceres/PareceresSPED_Rastreio-de-CCR.pdf. Accessed Sep 21, 2022.
3. Simon K. Colorectal cancer development and advances in screening. Clinical Interventions in Aging 2016;11:967–76.
4. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019;394:1467–80.
5. Chan A, Giovannucci E. Primary prevention of colorectal cancer. Gastroenterology 2010;138:2029–43.
6. Lee G, Malietzis G, Askari A, Bernardo D, Al-Hassi H, Clark S. Is right-sided colon cancer different to left-sided colorectal cancer? - A systematic review. Eur J Surg Oncol 2015;41:300–8.
7. Treanor D, Quirke P. Pathology of colorectal cancer. Clin Oncol 2007;19:769–76.
8. Kim B, Kim J, Kang G, Chang H, Kang D, Kim J, et al. Standardized pathology report for colorectal cancer, 2nd edition. J Pathol Transl Med 2020;54:1–19.
9. Sagaert X, Vanstapel A, Verbeek S. Tumor Heterogeneity in Colorectal Cancer: What Do We Know So Far? Pathobiology 2018,85:72–84.
10. Sveen A, Kopetz S, Lothe R. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11–32.
11. Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther 2018;18:251–66.
12. Yin L, Li J, Ma D, Li D, Sun Y. Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies. Oncol Lett 2020;19:3558–66.
13. Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic therapy in colorectal cancer. Cancer J 2018;24:165–70.
14. Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics 2013;10:55–67.
15. Mohamed S, Mohammed H, Ibrahim H, Mohamed E, Salah M. Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer 2019;50:23–34.
16. Liang J, Wang H, Xiao H, Li N, Cheng C, Zhao Y. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 2010;29:71.
17. Mousa L, Salem ME, Mikhail S. Biomarkers of angiogenesis in colorectal cancer. Biomark Cancer 2015;7:13–9.
18. Li P, Xiao ZT, Braciak TA, Ou QJ, Chen G, Oduncu FS. Association between Ki67 index and clinicopathological features in colorectal cancer. Oncol Res Treat 2016;39:696–702.
19. Tong G, Zhang G, Liu J, Zheng Z, Chen Y, Niu P, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC 8 stratification. Oncol Rep 2020;43:1187–98.
20. Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 2016;69:209–14.
21. Luo Z, Zhu M, Zhang Z, Ye F, Huang W, Luo X. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: A meta-analysis. BMC Cancer 2019;19:123.
22. Faratzis G, Tsiambas E, Rapidis A, Machaira A, Xiromeritis K, Patsouris E. VEGF and ki 67 expression in squamous cell carcinoma of the tongue: An immunohistochemical and computerized image analysis study. Oral Oncol 2009;45:584–8.
23. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Obermair A, Kimberger O, et al. Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecologic Oncol 2004;92:175–9.
24. Gheytanchi E, Mehrazma M, Madjd Z. Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Asian Pac J Cancer Prev 2014;15:3065–70.
25. Park S, Nam SJ, Keam B, Kim TM, Jeon YK, Lee SH, et al. VEGF and Ki-67 overexpression in predicting poor overall survival in adenoid cystic carcinoma. Cancer Res Treat 2016;48:518–26.
26. Chen JX, Deng N, Chen X, Chen LW, Qiu SP, Li XF, et al. A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev 2012;13:2229–34.
27. Martins S, Amorim R, Mota S, Costa L, Pardal F, Rodrigues M, et al. Ki-67 Expression in CRC lymph node metastasis does not predict survival. BioMed Res Int 2015;2015:131685.
28. Zheng S, Han MY, Xiao ZX, Peng JP, Dong Q. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003;9:1227–30.
29. Chung JY, Braunschweig T, Hong SM, Kwon DS, Eo SH, Cho H, et al. Assessment of vascular endothelial growth factor in formalin fixed, paraffin embedded colon cancer specimens by means of a well-based reverse phase protein array. Proteome Sci 2014;12:27.
30. George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 2001;3:420–7.
31. Chaudary N, Milosevic M, Hill R. Suppression of vascular endothelial growth factor receptor 3 (VEGFR3) and vascular endothelial growth factor C (VEGFC) inhibits hypoxia- induced lymph node metastases in cervix cancer. Gynecol Oncol 2011;123:393–400.
32. Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, et al. Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer. Oncology 2007;71:176–84.
33. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008;147:99–107.
34. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748–53.
35. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960–8.
36. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep 2015;11:1566–72.
37. Khalil K, Al-Hassawi B, Abdo J. Histopathological evaluation of colorectal carcinoma. Duhok Medical Journal. 2018;12:45–67.
38. Salminen E, Palmu S, Vahlberg T, Roberts P, Söderström K. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 2005;11:3245–9.
39. Jansson A, Sun XF. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 1997;105:730–4.
40. van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF, Peters GJ. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000;6:1063–72.